China-headquartered contract research, development and manufacturing organization (CRDMO) WuXi Biologics plans to increase the manufacturing capacity of its US facility...

Chinese contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics announced the planned spin-off and separate listing of its subsidiary WuXi...

Chinese CDMO WuXi Biologics plans to expand capacity in Germany in response to rising demand. The company will install a second filling line at Leverkusen and expects to...

WuXi STA has added two reactors at its Changzhou campus in China, enhancing capacity and capability at its TIDES contract research, development and manufacturing platform...

In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and...

WuXi STA has opened a sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its campus in Wuxi city, China, in response to rising demand...

Germany’s Merck has signed has an agreement with the Administrative Management Committee of Wuxi National High-Tech Industrial Development Zone to “significantly expand”...

China’s WuXI Biologics has agreed to buy Pfizer’s biologics manufacturing facilities in Hangzhou for an undisclosed price. The transaction is expected to close in the...